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status of Cardiac Transplantation with a Report ofthe First Year's 
Experience at Henry Ford Hospital 
Fraser M. Keith, MD,* Donald J. Magilligan, Jr, MD,* Jeffrey B. Lakier, MD,* and 
Conrad Drost, RN* 
Cardiac transplantation is now widely accepted as effective treatment for selected patients with end-
stage heart disease. Improvements in immunosuppressive treatment and monitoring in the past 15 
years have resulted in impressive one-year and five-year sur\'ival rates of 80% and 60%. In general, 
survivors have enjoyed a considerably improved quality of life. A cardiac transplantation program 
was initiated at Henry Ford Hospital in 1985, and a total of 15 patients received heart transplants in 
thefirst 12 months. Fourteen patients are currently alive and well at various stages posttransplant. 
This early clinical success has prompted the consideration of both combined heart-lung 
tramplantation and mechanical left ventricular support at Henrv Ford Hospital in the future. (Henry 
FordHosp MedJ 1986:34:197-201) 
A fter nearly a decade, cardiac transplantation reemerged in the late 1970s as effective treatment for selected patients 
with end-stage cardiac disease. Since then a rapid increase in 
both the number of recipients and transplant centers has oc-
cuned. An intemational registry for heart and heart-lung trans-
plant recipients was established in 1984 (I), The number of pa-
tients in the registry currendy exceeds 2,800; over 700 were 
accounted for in 1985 alone. Some authorities predict that as 
many as 2,000 cardiac transplants per year could be performed 
in the United States using cunent recipient and donor selection 
criteria (2,3). 
The major stimulus for renewed interest in cardiac transplan-
tation is the increased survival and freedom from morbidity af-
forded by cyclosporine immunosuppression. Expected survival 
rates for cardiac transplant recipients in 1986 are 80% and 60% 
at one and five years, respectively. The quality of life is cleariy 
improved following cardiac transplantation, and many recip-
ients resume full-time employment. 
The cardiac transplantation program at Henry Ford Hospital 
was initiated in 1985. This was a cooperative multilevel and 
multidisciplinary venture throughout the hospital. After three 
months of laboratory experiments, the first human cardiac trans-
plant at Henry Ford Hospital was perfonned in April 1985. A 
total of 15 patients received transplants during the first 12 months 
ofthe program. To date, 14 of these 15 patients are alive and well 
at various stages of posttransplant; the one death was attributed 
to disseminated aspergillosis. This presentation oudines some 
ofthe important issues in human cardiac transplantation and dis-
cusses the results of the recent Henry Ford Hospital experience. 
Recipient Selection 
Careful recipient selection is one of the most important deter-
minants of success in a cardiac transplant program. Medical, 
psychosocial, and financial issues must be considered. At 
Henry Ford Hospital a pretransplant evaluation is performed by 
a committee which consists of the medical-surgical group, a so-
cial worker, psychiatrist, and chaplain. Full support of the trans-
plant committee must be obtained before an individual is added 
to the list of patients awaiting transplantation. Additional input 
is obtained from specialists in infectious diseases, immuno-
pathology, pathology, hypertension/nephrology, nursing, and 
rehabilitation. 
Cardiac transplantation is considered for patients with end-
stage cardiac disease only when other, more conventional treat-
ment has failed or is contraindicated. As a group, these patients 
have an extremely poor prognosis. Data from Stanford Univer-
sity show a mean survival rate of six weeks for patients who have 
been accepted for transplantation but for whom no suitable do-
nor can be found (4). Despite this survival advantage, the main 
reason for cardiac transplantation at Henry Ford Hospital is the 
symptomatic relief of severe congestive heart failure. 
The primary diagnoses of the 15 patients who received trans-
plants at Henry Ford Hospital in 1985 are listed in Table I . Na-
Table 1 
Primary Diagnosis 
Idiopathic cardiomyopathy 
Ischemic cardiomyopathy 
Valvular heart disease 
Olher 
4 patients 
8 patients 
2 patients 
I patient 
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Table 2 
Criteria for Recipient Selection: Optimal Conditions 
Age less than 55 years 
Terminal cardiac disease despite optimal conventional medicaysurgical therapy 
Life expectancy less than one year 
Noncardiac function normal or reversibly impaired 
Pulmonary vascular resistance less than 2 Wood units 
No active infection, cancer, or other systemic illness 
Good psychosocial profile 
Good record of medical compliance 
Adequate finances 
Well-informed and motivated 
tionally, ischemic cardiomyopathy is probably the most frequent 
indication for cardiac transplantation, and more patients are 
being refened after unsuccessful myocardial revascularization 
with or without concomitant valve or aneurysm procedures. 
Moribund patients with an intraaortic balloon pump and receiv-
ing inotropic support or other mechanical support are also a 
growing fraction of the cardiac transplant population. Overall, 
clinical judgment is probably as important in determining the 
optimal timing for transplantation as are the objective measures 
of cardiac failure, such as cardiac index, ejection fraction, and 
end-diastolic pressure. The optimal recipient criteria based on 
cunent opinion are outlined in Table 2 (5). 
The age criteria for transplantation have been challenged by 
many groups. Patients older than 55 years have had transplants 
and, if otherwise carefully selected, do as well as their younger 
counterparts. Undoubtedly, the upper age limit at an institution 
is partly determined by the number of available donors and the 
number of young recipients already on the waiting list. The de-
mographics of the cardiac transplant recipients at Henry Ford 
Hospital are provided in Table 3. 
Elevation ofthe pulmonary vascular resistance detected at the 
time of right heart catheterization is a significant concern for 
patients with long-standing congestive heart failure. The ortho-
topically transplanted heart is poorly prepared to funcrion 
acutely with a high afterload on the right ventricle. Fortunately, 
patients rarely have fixed elevations of pulmonary vascular re-
sistance even in the setting of long-standing heart disease. At 
Henry Ford Hospital an attempt is made to normalize pulmonary 
resistance during catheterization by administration of oxygen 
and systemic vasodilators. Alternately, these patients might be 
considered for combined heart and lung transplantation or het-
erotopic heart transplantation. 
The goal of cardiac transplantation is successful rehabilitation 
ofthe patient with a return toward a normal level of activity. 
Since life expectancy after cardiac transplantation is unlikely to 
be normal when compared with age-matched controls, the trans-
plant recipient should be highly motivated and have a realis-
tic attitude and definite ambition. Stress is always present, and 
good emotional and family support is essential. Alcoholism and 
dmg abuse are contraindications for transplantation. The best 
recipients are mature, intelligent individuals with a good record 
of medical compliance and a short history of disability. 
Donor Selection 
Cunent optimal donor criteria are presented in Table 4 (6,7). 
Coronary artery disease is so prevalent in North America that 
Table 3 
Recipient Demographics 
Age 
Sex (No.) 
Race (No.) 
45 years (mean) 
Males (13) 
Caucasian (12) 
29 to 58 years (range) 
Females (2) 
Black (3) 
generally only younger donors are chosen. Nevertheless, a 
growing donor shortage and increasingly ill recipients have 
forced some groups to extend the donor age criteria. In most 
cases, a careful review of the donor's history, physical examina-
tion, electrocardiogram, and echocardiogram is sufficient to de-
tect significant cardiac abnormalities. Cardiac catheterization 
and coronary angiography are rarely indicated. Though it is not 
critical, an attempt is made to match the size of donor and recip-
ient. Long-standing cardiac failure and pulmonary hypertension 
result in global cardiomegaly and frequent enlargement of the 
great vessels. In these circumstances it is technically easier to 
graft a heart from a larger donor. Similar allowances are also 
made for recipients with high pulmonary vascular resistance. 
The donor's and recipient's ABO systems must be compati-
ble, but matching the minor blood group antigens is unneces-
sary. HLA matching is probably beneficial for cardiac recip-
ients, but time constraints and the limited donor pool prevent 
routine use. Prospective HLA antibody screening is performed 
for all potential cardiac recipients. Fortunately, cytotoxic anti-
bodies against HLA antigens are much less common in cardiac 
than in renal transplant candidates. Results of the fonnal donor-
recipient cross-match are unnecessary preoperatively unless 
screening indicates recipient positivity against 15% or more ofa 
panel of random donor lymphocytes. We have yet to encounter a 
patient with this degree of positivity. Donors are also screened 
for the presence of potentially transmissible diseases such as 
AIDS, hepatitis-B, and nonprimary central nervous system can-
cer A significant history of recent dmg abuse, particularly intra-
venous dmgs, precludes cardiac donation. 
The mechanism of brain death has not been shown to influ-
ence the results of organ transplantation. In our experience at 
Henry Ford Hospital, the two major causes of brain death have 
been traumatic brain injury and cerebral hemorrhage from 
vascular abnormalities. Brain death sets in motion a complex 
chain of physiologic events which uldmately result in cardio-
vascular collapse and arrest of the circulatory system. The 
potential organ donor requires careful monitoring to main-
tain homeostasis. Fluid balance and electrolyte management are 
complicated by the presence of diabetes insipidus. Temperature 
regulation is disturbed with the appearance of either hyperther-
mia or hypothermia. Sepsis from pneumonia, urinary tract 
infections, or traumatic or surgical wounds must be treated ag-
gressively with appropriate antibiotics. Initially, hypotension 
resulting from fluid restriction, diabetes insipidus, or diuretic 
therapy can be reversed by fluid administration. Judicious use of 
dopamine and colloid are also beneficial in maintaining car-
diovascular stability. The dosage limits or duration of dopa-
mine administration have not been cleariy established. However, 
most cardiac groups find that doses of over 5 (jig/kg/min are 
excessive. 
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Table 4 
Criteria for Donor Selection: Optimal Conditions 
Age: Males less than 35 years of age, females less than 40 years of age. 
Size: Within 20% body weight of the recipient. 
ABO blood group compatible. 
Hemodynamically stable: Dopamine less than 5 p-g/kg/min. 
Absence of significant cardiac history or injury. 
Absence of transmissible diseases: hepatitis, AIDS, cancer, etc. 
Not enough thanks can be given to the families of the donors 
who make these unselfish gifts at a time of great personal grief. 
Increasing public awareness of the success of transplantation 
combined with progressive policy decisions on the part of gov-
emment at multiple levels have helped increase the number of 
organ donors. We expect that required-request legislation will 
have a further positive effect. Each hospital must fonnulate its 
own definitions of brain death, although nationally recognized 
guidelines are available (8,9). Contact with a number of excel-
lent regional organ procurement networks ensures optimal uti-
lization of the organs to be donated once brain death has been 
established. 
Cardiac IVansplantation: The Operation 
The surgical procedure for orthotopic cardiac transplantation 
was originally described by Lower and Shumway (10) and later 
modified by Barnard (II), Initially, simultaneous donor and re-
cipient operations were performed in adjacent operating rooms 
to minimize the period of cardiac graft ischemia, Cunent hy-
pothermic cardioplegic techniques ensure good myocardial 
preservation for periods of up to four hours in humans and con-
siderably longer in animals. This has increased the donor pool 
by allowing donor organ procurement up to 1,000 miles from the 
site of implantation (12,13). Close coordination between donor 
and recipient teams is required to minimize graft ischemic 
times, particulariy at these long distances. Fortunately, our 
transplant program has been able to secure all donors from 
within a 250 mile radius. Mean ischemic time was 107 minutes 
with a range of 53 to 184 minutes. 
Cardiac recipients present challenging problems to the anes-
thetist. The induction and prebypass phases require careful 
monitoring and titration of anesthesia to maintain hemodynamic 
stability. Recipients at Henry Ford Hospital have their blood 
ultrafiltered during cardiopulmonary bypass. Our clinical 
impression is that this reduction in total body water improves 
pulmonary function and facilitates early extubation post-
operatively. The most frequent intraoperative problem in this 
group of patients is bleeding. Major risk factors that cause 
bleeding are reoperation, preoperative anticoagulant therapy, 
and congestive hepatic dysfunction. 
All grafts have functioned sufficiently after implantation to 
allow weaning from cardiopulmonary bypass. Patients routinely 
receive small doses of inotropes postoperatively. Early in our ex-
perience at Henry Ford Hospital, we learned that right-sided he-
modynamics were equally if not more important than left-sided 
hemodynamics after cardiac transplantation. Consequently, a 
Table 5 
Biopsy Interpretation 
Grade Histology 
No rejection No infiltrate 
Mild rejection Mononuclear infiltrate 
Perivascular to interstitial location 
No myocyte necrosis present 
Moderate rejection Mononuclear interstitial infiltrate 
Mild to moderate myocyte necrosis 
Severe rejection Marked myocyte necrosis 
Infiltrate with polymorphonuclear leukocytes or 
hemorthage 
pulmonary artery thermodilution cardiac output catheter is now 
inserted routinely before separation from cardiopulmonary by-
pass. Reduction of right ventricular afterload with nitroglycerin 
or prostaglandins has been helpful in some patients. 
Immune Suppression 
Early in the cardiac transplant experience the two major 
sources of morbidity and mortality were rejection and infection. 
The 12-month survival rate in 1968 was 20%, with almost all of 
the deaths occurring from rejection and infection within the first 
three months after transplantation. Clearly, the antirejecdon 
protocols available then had too nanow a margin between over 
and under immune suppression. 
In the 1970s cardiac transplantation fell into disfavor, and only 
a few groups continued this procedure. Two notable achieve-
ments were made at Stanford University during this period: in-
troduction of endomyocardial biopsy as a routine clinical tool in 
the evaluation of rejection (14), and development of antihuman 
thymocyte sera for prophylaxis and treatment of rejecdon (15). 
By the mid-1970s, the 12-month transplantation survival rate at 
Stanford improved to 60%, and other American, European, and 
South African centers began to report similar results. Endo-
myocardial biopsy is the "gold standard" against which all 
other diagnostic techniques for rejection must be compared. It is 
a simple and relatively safe procedure that can be repeated as 
often as necessary. The histologic classification of cardiac rejec-
tion has been well described (16) and is presented in Table 5. 
Although the threat is always present, the incidence of rejec-
tion declines markedly after the first three months (17). Pres-
ently, almost all patients have at least one histologically diag-
nosed acute rejection episode in the first three months post-
transplant. Antirejection surveillance, therefore, is most intense 
during this period, and endomyocardial biopsies are repeated 
every one or two weeks. Beyond the three-month period, the in-
terval between successive biopsies is gradually extended; cur-
rently, one-year survivors at Henry Ford Hospital are biopsied 
every three months. 
Another major advance in the history of cardiac transplanta-
tion was the discovery of cyclosporine, a naturally occuning 
peptide isolated from two species of soil fungi. This remarkable 
dmg has potent and specific effects on cell-mediated immunity. 
Initially, cyclosporine was used as the sole immunosuppressive 
dmg, but clinical experience has shown it to be most effective 
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Table 6 
Immune Suppression: Regimen for Cardiac 
Transplant Recipients 
Steroids 
ALG 
Cyclo.sporine 
Azathioprine 
Methylprednisolone intravenously. 
500 mg intraoperatively. 
IOO mg every 8 hours for 24 hours. 
50 mg every 8 hours for 24 hours. 
Prednisone orally 1 mg/kg/day tapered to 
0.2 mg/kg/day by 4 to 6 weeks. 
10 to 15 mg/kg/day intravenously to reduce total 
peripheral blood lymphocytes less than 200. 
Stop when serum cyclosporine level greater than 
100 ng/mL. 
6 to 8 mg/kg/day orally. Start when taking fluids 
orally and renal function adequate. 
Adjust every 12-hour dose to obtain targeted 
trough serum level. 
I to 2 mg/kg/day orally. Start when taking fluids 
orally and maintain total leukocytes greater 
than 5,000 and platelets greater than 100,000 
in peripheral blood. 
when combined with either prednisone or azathioprine. The im-
munosuppressive protocol in use at Henry Ford Hospital is pre-
sented in Table 6. 
Cyclosporine therapy has been responsible for the latest 15% 
to 20% across-the-board improvement in survival rates follow-
ing cardiac transplantation. It has nanowed the success rate dif-
ferences between experienced centers and those just starting 
transplant programs. This has encouraged rapid proliferation of 
transplant centers worldwide. 
When cyclosporine therapy is compared with "conven-
tional" immunosuppressive regimens (those used in the pre-
cyclosporine era), mortality from rejection and infection is dra-
matically reduced (17). The incidence of acute rejection is 
probably unchanged, but the rejection process is slowed and 
more amenable to reversal. Preservation of humoral and non-
specific immunity also results in fewer deaths from infection, 
ahhough the overall incidence of infection probably remains 
unchanged. 
Complications of long-term immunosuppressive therapy in-
clude an increased risk of opportunistic infections and cancer 
(18). The development of accelerated atherosclerosis within the 
graft is one complication specific to cardiac transplantation and 
is a leading cause of late death. Routine, annual coronary an-
giography is performed to detect this complication, and signifi-
cant coronary lesions are an indication for retransplantation. 
Cyclosporine has its own special long-term problems, notably 
nephrotoxicity and the almost universal incidence of hyperten-
sion among cardiac transplant recipients. Acute cyclosporine 
nephrotoxicity is frequendy observed posttransplant in patients 
with preoperative renal dysfunction (19). This complication is 
usually manifested as acute oliguric renal dysfunction in the im-
mediate posttransplant period. For this reason, we avoid the 
perioperative use of cyclosporine and rely on antilymphoblast 
globulin for immune suppression during the first two to three 
days. Cyclosporine is administered when cardiorespiratory, 
gastrointestinal, and renal function have stabilized. Cyclo-
sporine levels are monitored daily, and the dose is adjusted fre-
quently to ensure optimal efficacy and minimum toxicity. When 
more insidious chronic nephrotoxicity of cyclosporine occurs 
after several months of therapy, serial monitoring of renal func-
tion reveals slow deterioration. This has been the subject of 
much recent concern and research. Cyclosporine analogs, mul-
tidrug protocols, and determination of optimum long-term 
cyclosporine levels should diminish this problem in the future. 
Future Directions 
The major breakthrough for solid organ transplantation will 
come with the development of methods for inducing specific 
tolerance. This will obviate the need for long-term immuno-
suppressive therapy and eliminate the associated problems of in-
fection, cancer, and adverse dmg reactions. Much experimental 
progress should affect clinical practice soon. 
New analogs of cyclosporine which are undergoing clinical 
trials may or may not have advantages over the parent com-
pound. Monoclonal antibodies against specific classes of human 
T-cells are now available for clinical use and are effective in 
treatment of resistant-rejection episodes. Their ultimate role, 
however, remains to be defined. Other forms of immune modifi-
cation by pretransplant blood transfusion or total lymphoid ina-
diation are beneficial for renal transplantation but are not yet 
widely practiced in cardiac transplantation. 
Short-term mechanical support or replacement ofthe heart is 
viewed as a bridge to cardiac transplantation. These devices are 
effective in salvaging patients until suitable donors can be 
found, but the demand for cardiac donors already exceeds the 
supply. Thus, the "bridge" concept does not solve the problem; 
it merely increases the number of seriously ill patients awaiting 
transplantation. Xenografts and a new generation of totally im-
plantable mechanical devices are potential sources for cardiac 
replacement in the future. 
The first year's experience in cardiac transplantation at Henry 
Ford Hospital has been exceptionally gratifying for everyone in-
volved. Future directions for the program include the initiation 
of combined heart-lung transplantation and temporary left ven-
tricular support with a mechanical device. We expect the next 12 
months to be equally exciting. 
Addendum 
Twenty-five patients have undergone orthotopic cardiac trans-
plantation at Henry Ford Hospital as of August 1986. Five pa-
tients have been followed in excess of one year, and all survivors 
are cunently well. 
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